ProjectStudie CA209-511 (EUDRACT Number 2015-004920-67)
Basic data
Title:
Studie CA209-511 (EUDRACT Number 2015-004920-67)
Duration:
01/07/2016 to 28/02/2022
Abstract / short description:
Studie CA209-511: Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with
Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in
Subjects with Previously Untreated, Unresectable or Metastatic Melanoma
(CheckMate 511: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 511)
Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in
Subjects with Previously Untreated, Unresectable or Metastatic Melanoma
(CheckMate 511: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 511)
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Tampouri, Ioanna
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Spänkuch, Iris
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Lomberg, Diana
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Thomas, Ioannis
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Wilhelmi-Dick, Julia-Alexandra
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
Brüssel, Belgium